The closing was expected, not a fresh surprise. Apogee says the merger agreement was signed on June 18, 2026, and the transaction closed on September 3, 2026, so the market had already been working from a known cash-sale outcome rather than awaiting a clinical or financial update.
| Deal term | Filing detail |
|---|---|
| Cash consideration | $135.11 per share (Merger Consideration) |
| Total equity value | Approximately $10.9 billion (Item 5.01) |
| Executive parachute gross-up cap | $12.5 million (Item 5.02 / Exhibit 10.1) |
| Nasdaq trading suspension | September 4, 2026 (Item 3.01) |
The filing delivers the agreed economics in full. Each eligible share was converted into the right to receive $135.11 in cash, while options, restricted stock units, restricted stock and warrants were handled according to the merger terms.
Apogee is no longer an independent public company. AbbVie now owns Apogee indirectly and funded the approximately $10.9 billion equity transaction with cash on hand and debt; Apogee’s shareholders retain only the right to receive the merger consideration. 〔0〕
The remaining changes are administrative and organizational, not incremental value creation. Apogee requested delisting, trading is scheduled to be suspended on September 4, 2026, all existing directors resigned, and the executive officers ceased serving in their roles. 〔1〕 Because those consequences were inherent in the previously announced acquisition, this is best read as confirmation of a priced-in transaction rather than a new positive or negative catalyst.
Read the original 8-K on SEC EDGAR ↗